ATXS Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -1.78%, SMA50 -1.3%, SMA200 51.97%). The stock’s 14-day RSI is 46.09 (neutral), while the ATR of 0.23 points to moderate volatility. The stock remains hovering near 52-week lows, trading -5.34% below its high and over 253.87% above its low.

Astria Therapeutics, Inc. generated EPS of -$2.15 over the past year. Five-year average earnings growth is 34.65%. Wall Street analysts project EPS growth of -5.63% annually over the next five years. The latest quarter delivered EPS of $nan. The next quarter is forecast at -$0.54. Next year's EPS is expected at -$4.49. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $49.00 to $13.00. The high target offers 289.51% upside. The low target suggests 3.34% downside. The mean target is $21.86. This offers 73.77% upside. The prior quarter beat by -6.56%. Over the last six quarters, Apple has recorded several small beats. These include 16.22% in August 12, 2024.

The stock is currently mid-range between its 52-week high and low $3.56 and $13.29. With a market capitalization of about $718.13 million, Astria Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.02). Key stats such as the average daily volume over the past year has been around 1.07 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Astria Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jill C. Milne, the company employs approximately 78 people and listed since June 25, 2015. Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.

Astria Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.97. This means the shares are trading above this model’s fair value.

Astria Therapeutics, Inc. has 57.08 million shares outstanding. The public float is 39.18 million shares, elevated short interest at 12.65% of float. This equals 5.75 million shares. The short ratio is 4.7 days. Institutional investors hold 95.28% of the float. Insiders own 0.48%. PERCEPTIVE ADVISORS LLC holds 4.87 million shares, Clarus Lifesciences II, L.P. has 2.75 million shares and GALAKATOS NICHOLAS has 2.75 million shares.

Astria Therapeutics, Inc. trades at a P/E ratio of -5.88, slightly below the S&P 500 average, with a price-to-sales ratio of 1017.18 and a price-to-book ratio of 3.13 trading at moderately above to book value. The P/FCF stands at -5.97, also below market averages.

Our AI price prediction model suggests that Astria Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.05%, with price expected at $12.07 by February 05, 2026, within a range of $11.92 to $12.24 3-Month Outlook: Projected fall of -9.54%, reaching $11.38 by April 22, 2026, with a range of $11.01 to $11.77. 1-Year Outlook: Projected gain of 276.87%, with price at $47.41 by January 22, 2027, within a range of $45.92 to $62.01.

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares are flat -4.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Astria Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.88. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $20.97, suggesting 66.69% upside. Our AI forecast model points to short-term weakness (-4.05% over two weeks), a medium-term fall (-9.54% over three months), and a longer-term gain (276.87% over one year), with expected trading ranges indicating moderate volatility.